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Abstract
We have previously shown that oxidative stress within the tumor microenvironment causes phosphatidylserine
(PS) to redistribute from the inner to the outer membrane leaflet of the endothelial cells (EC) creating a highly specific
marker for the tumor vasculature. Because the distribution of phosphatidylethanolamine (PE) and PS within the
membrane is coregulated, we reasoned that PE would also be localized in the outer membrane leaflet of tumor
EC. To demonstrate this, the PE-binding peptide duramycin was biotinylated and used to determine the distribu-
tion of PE on EC in vitro and in vivo. Exposure of cultured EC to hypoxia, acidity, reactive oxygen species, or irra-
diation resulted in the formation of membrane blebs that were intensely PE-positive. When biotinylated duramycin
was intravenously injected into tumor-bearing mice, it preferentially localized to the luminal surface of the vascular
endothelium. Depending on tumor type, 13% to 56% of the tumor vessels stained positive for PE. PE-positive ves-
sels were observed in and around hypoxic regions of the tumor. With the exception of intertubular vessels of the
kidney, normal vessels remained unstained. To test the potential of PE as a biomarker for imaging, duramycin was
conjugated to the near-infrared fluorophore 800CW and used for optical imaging of RM-9 prostate carcinomas. The
near-infrared probe was easily detected within tumors in live animals. These results show that PE, like PS, becomes
exposed on tumor vascular endothelium of multiple types of tumors and holds promise as a biomarker for nonin-
vasive imaging and drug targeting.
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Introduction
In normal cells, the aminophospholipids phosphatidylserine (PS) and
phosphatidylethanolamine (PE) are asymmetrically distributed across
the plasma membrane with essentially all the PS and the majority of
the PE localized in the cell’s inner membrane leaflet [1,2]. This mem-
brane lipid asymmetry is maintained by a group of P-type ATPases
known as aminophospholipid translocases (APTLs) that catalyze the
active transport of PS and PE from the external to the internal leaflet
of the plasma membrane [3]. Unlike normal cells, apoptotic cells and
tumor cells lose their capacity to maintain PS asymmetry resulting in
the appearance of the lipid in the cells’ outer membrane leaflet. The
expression of PS at the cell surface inhibits immune responsiveness
and, in the case of apoptotic cells, also serves as a recognition ligand
and binding site for phagocytes [4,5]. PE has also been shown to be
exposed on apoptotic cells, but it has not been associated with a spe-
cific function [6].
Increases in intracellular [Ca2+] as a result of transcriptional acti-
vation or exposure to environmental stress can also cause loss of
membrane asymmetry. Influx of exogenous Ca2+ or Ca2+ released
from intracellular stores inhibits APTLs and, at the same time, acti-
vates ATP-binding cassette transporters and phospholipid scram-
blases that randomize all membrane phospholipids between leaflets
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resulting in a complete loss in plasma membrane lipid asymmetry
[7,8]. Environmental stress also activates sphingomyelinases that
cleave sphingomyelin (SM) to ceramide [9,10]. Ceramide destabilizes
the bilayer, activates proapoptotic signaling pathways, and promotes
membrane blebbing [11,12]. Thus, cellular stress and activation can
promote the exposure of aminophospholipids on the cell surface
through multiple pathways. Indeed, unlike quiescent normal endo-
thelium, there is significant environmental stress imposed on the tu-
mor endothelium by acidity, reactive oxygen species (ROS), and
transient hypoxia, which results in the redistribution of PS to the cell
surface [13]. Consequently, PS becomes exposed on vascular endo-
thelium of all tumor types so far examined [14,15]. Because both PS
and PE are coregulated by the same transporters, [2] the expression
of cell surface PS on tumor EC raises the possibility that PE is also
expressed on the surface of tumor blood vessels.
Duramycin (MWt = 2013 Da) is a highly specific PE-binding
peptide produced by the bacteria Streptoverticillium cinnamoneus.
Duramycin binds PE at a 1:1 molar ratio with a K d of 4 to 6 nM,
an unusually high affinity for a small, ligand-binding peptide [16].
Duramycin is the smallest polypeptide known to have a defined
three-dimensional binding pocket and recognizes ethanolamine phos-
pholipids with exclusive specificity [16] by fitting over the etha-
nolamine head group like a glove [17]. The hydrophobic binding
pocket is stabilized by three internal thioether linkages that make
the peptide resistant to heat and proteolytic degradation [18]. Pharma-
cokinetic studies in rats have shown that duramycin is rapidly cleared
from the blood stream with a serum half-life of less than 4 minutes
[19]. 99mTc-labeled duramycin binds to PE exposed on apoptotic
and necrotic cells and has been used successfully for the in vivo imag-
ing of acute myocardial infarction [19].
In this report, we used duramycin to show that PE becomes spe-
cifically exposed on the surface of tumor EC and that treatment of
cultivated EC with known tumor-associated stresses causes the for-
mation of PE-positive blebs on the cell membrane. In vivo studies
revealed that labeled duramycin specifically localized to the vascular
endothelium in multiple tumor types. Duramycin was also effective
at imaging subcutaneous tumors. Taken together, these findings in-
dicate that externalized PE may be a general marker of tumor vas-
culature and suggest that duramycin possesses the specificity and
pharmacokinetic properties to make it an effective agent for specifi-
cally targeting the tumor vasculature with imaging agents and/or
therapeutic drugs.
Materials and Methods
Materials
Duramycin from S. cinnamoneus, bovine serum albumin (BSA),
o-phenylenediamine dihydrochloride (ODP), and vascular endothe-
lial growth factor (VEGF) were purchased from Sigma (St Louis,
MO). Sulfo-NHC-LC biotin was obtained from Pierce (Rockford,
IL). IRDye 800CW NHS Ester was obtained from LI-COR Bio-
sciences (Lincoln, NE). Dulbecco modified Eagle tissue culture me-
dium, Dulbecco phosphate-buffered saline (PBS) containing Ca2+
and Mg2+, glutamine, and fetal bovine serum (FBS) were obtained
from HyClone (Thermo Scientific, Logan, UT). Alexa Fluor 488–
conjugated streptavidin, Alexa Fluor 350–conjugated streptavidin, and
Prolong Gold mounting medium with 4′,6-diamidino-2-phenylindole
(DAPI) were obtained from Molecular Probes (Invitrogen, Carlsbad,
CA). Horseradish peroxidase–conjugated streptavidin and Cy3-
conjugated streptavidin were purchased from Jackson ImmunoResearch
Laboratories (West Grove, PA). Immulon 1B 96-well microtiter plates
were obtained fromThermo LabSystems (Franklin, MA). LUMITRAC
96-wellmicrotiter plates were obtained fromGreiner Bio-One (Monroe,
NC). PE, phosphatidylcholine (PC), PS, SM, phosphoinositol (PI),
phosphatidic acid (PA) and phosphatidylglycerol (PG) were obtained
from Avanti Polar Lipids (Alabaster, AL).
Antibodies
The PS-targeting antibody bavituximab is produced under serum-free
conditions by Peregrine Pharmaceuticals, Inc (Tustin, CA). Bavituximab
requires 1:1 addition of human β2-glycoprotein to bind PS. Rituxan is
a human monoclonal antibody that binds human CD20 and was
obtained from the UT Southwestern Pharmacy. Rat antimouse CD31
antibody was purchased from BD Biosciences (San Jose, CA). Goat
antihuman immunoglobulin G (IgG) conjugated to Cy2, goat antirat
IgG conjugated to Cy3, and biotinylated goat antirat IgG secondary
antibodies were obtained from Jackson Immunoresearch Laboratories
(West Grove, PA).
Synthesis of Duramycin Conjugates and Control Peptides
Duramycin was reacted through its free amino groups with an N -
hydroxysuccinimide (NHS) ester of a long-chain (adipic) derivative
of L-biotin at a molar ratio of 1:1.1. Briefly, NHS-biotin in dimethyl
sulfoxide was rapidly mixed with duramycin in PBS. The reaction
was allowed to proceed for 2 hours. Unreacted biotin was removed
by dialysis. The product corresponding to one molecule of duramycin
linked to one molecule of biotin was purified by high-performance
liquid chromatography. Mass spectrometry confirmed a molecular
mass of 2352 Da (Figure 1A). The duramycin–L-biotin conjugate
(DLB) was supplemented with an equal weight of unlabeled duramy-
cin for all assays, as its addition strengthened PE binding. The control
peptide linear duramycin (linDUR) was synthesized by Biosynthesis,
Inc (Lewisville, TX) and has the same sequence as duramycin except that
thioether-linked amino acids were substituted with alanines. linDUR
was biotinylated to produce the control peptide linear–duramycin-L-
biotin (linDLB). linDLB was also supplemented with an equal weight
of unlabeled duramycin for all assays.
Duramycin was reacted with the NHS ester of IRDye 800CWat a
1:1 molar ratio as described above. The product consisting of one
molecule of duramycin linked to one molecule of 800CW was pu-
rified by high-performance liquid chromatography. Mass spectrom-
etry confirmed a molecular mass of 2998 Da (Figure 1B). linDUR
reacted with IRDye 800CW produced the control peptide referred
to as 800CW-linDUR. Both 800CW-DUR and 800CW-linDUR
were supplemented with an equal weight of unlabeled duramycin
for all assays.
Cells
Adult bovine aortic endothelial (ABAE) cells were obtained form
Clonetics (Walkersville, MD). RM-1 mouse prostate carcinoma,
RM-9 mouse prostate carcinoma, 4T1 mouse breast carcinoma,
B16 mouse melanoma, and A549 human lung carcinoma cells were
obtained from American Type Cell Collection (Rockville, MD).
MDA-MB-231 human breast carcinoma cells were provided by
Dr Robert Kerbel (Sunnybrook Health Sciences Center, Toronto,
Ontario, Canada). All cells were maintained in Dulbecco modified
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Eagle medium supplemented with 10% FBS and 2 mM L-glutamine.
Cells were trypsinized with 0.25% trypsin and 2.1 mM EDTA
(Mediatech Inc, Manassas, VA).
Growth of Subcutaneously Implanted Tumors
For localization studies, 106 RM-1, RM-9, or B16 cells were in-
jected into the right-hind flank of male C57BL/6 mice (UTSW
breeding core). A549 cells (5 × 106 cells) were injected into the
right-hind flank of female athymic nu/numice (Charles River, Fredrick,
MD). Tumors were allowed to grow to a volume of 0.7 to 1.0 cm3.
Orthotopic MDA-MB-231 and 4T1 Breast Carcinoma Models
Female nu/nu or severe combined immunodeficient mice were
purchased from Charles River. MDA-MB-231 or 4T1 cells (5 ×
106) suspended in 0.1 ml were implanted into the mammary fat
pad as described previously [20]. Briefly, mice were anesthetized,
and a 5-mm incision was made in the skin over the lateral thorax.
The mammary fat pad was exposed to ensure the correct site of im-
plantation, and tumor cells were injected with a 25-gauge needle.
The incision was closed with a wound clip that was removed 5 to
7 days later.
MMTV-PyMT Transgenic Mice
Mouse mammary tumor virus (MMTV) promoter–driven expres-
sion of polyoma middle T antigen (PyMT) results in mammary
gland–specific adenocarcinoma formation [21]. Female MMTV-
PyMT mice were obtained from the laboratory of Dr Rolf Brekken
at UT Southwestern Medical Center (Dallas, TX).
Antiphospholipid ELISAs
To test the binding of DLB and 800CW-DUR, phospholipids
were dissolved in n-hexane (10 μg/ml), and 50 μl of this solution
was added to wells of Immulon 1B or LUMITRAC 96-well plates.
The solvent was evaporated at room temperature, and the plates were
blocked for 1 hour with 5% FBS dissolved in PBS. DLB and
800CW-DUR were diluted in blocking buffer at an initial concen-
trations of 1 and 10 μg/ml, respectively, and twofold dilutions were
Figure 1. Lipid specificity of the PE binding probes DLB and 800CW-DUR. (A) Structure of duramycin-linked biotin (DLB) and ELISA
showing DLB binds specifically to PE. (B) Structure of duramycin conjugated to the near-infrared fluorophore IRDye 800CW (800CW-
DUR) and ELISA showing that 800CW-DUR also retains binding specificity for PE. The structures show conjugation through the pre-
ferred lysine, although conjugation can also occur at the N-terminus.
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performed in a separate 96-well plates (100 μl/well). Phospholipid-
coated plates were washed with PBS, and DLB and 800CW-DURwere
transferred from dilution plates to Immulon 1B and LUMITRAC
plates, respectively. The plates were incubated for 1 hour at room tem-
perature and then washed. Bound 800CW-DURwas detected using an
Odyssey imaging system (LI-COR Biosciences, Lincoln, NE). Bound
DLB was detected using HRP-conjugated streptavidin (1:2000 in
blocking buffer) and ODP substrate. The optical density of ODP
was read at 490 nm using a microplate reader (BioTek Instruments,
Winooski, VT).
Hemolysis Assay
Fresh mouse blood was treated with heparin (15 IU/ml) and
centrifuged (300g for 5 minutes) to sediment the red cells. After
three washes, the red cells were resuspended in 10× the original vol-
ume of blood. Duramycin or DLB was serially twofold diluted in
PBS in 100-μl volumes in 96-well round-bottomed microplates.
The red cell suspension (100 μl/well) was added. The plates were
kept at room temperature for 1 hour. Supernatants were removed,
and their absorbance was measured at 575 nm in an ELISA reader.
Immunohistochemical Detection of Exposed PE on the Surface
of Cultured Endothelial Cells
ABAE cells were cultured in eight-well chamber slides (BD Falcon,
Bedford, MA) until approximately 80% confluent. To induce PE ex-
posure, cells were irradiated with 5 Gy 24 hours before staining. Un-
treated cells were used as a control. Cells were incubated with DLB
(0.5 μg/ml) dissolved in culture media. linDLB (0.5 μg/ml) was used
as a negative control. Bavituximab (1 μg/ml) was used as a positive
control for detection of PS. The cells were then washed with PBS and
fixed with 4% paraformaldehyde for 10 minutes. Excess aldehyde
groups were quenched with 50 mM ammonium chloride for 5 min-
utes. Biotinylated peptides were detected by incubating Alexa Fluor
488– or Cy3-conjugated streptavidin (1:1000 in 1% BSA) for 30 min-
utes. Cell membranes were permeablized with 0.5% Triton X-100
(5 minutes), and cytoskeletons were stained with Texas Red–labeled
phalloidin (1:200 in 1% BSA; 30 minutes). Cell nuclei were counter-
stained with DAPI.
Effect of ROS, Hypoxia, pH, and VEGF on PE Exposure in
Cultured EC
For all treatments, ABAE cells were cultured in 75-cm2 flasks
(Corning, Inc, Lowell, MA) until approximately 80% confluent.
To mimic ROS in tumors, cells were treated with 10 μM H2O2 in
serum-free medium for 1 hour. To study the effect of hypoxia, flasks
of cells were placed in a humidified normoxic atmosphere (21% O2,
5% CO2) for 48 hours before being transferred to a humidified hyp-
oxic atmosphere (1% O2, 5% CO2, 94% N2) in a sealed chamber
(BioSpherix, Lacona, NY). The cells were incubated in the hypoxic
chamber at 37°C for 24 hours and were then returned to a normoxic
environment for 4 hours at 37°C. To study the effect of acidity, cells
were incubated for 24 hours in bicarbonate-free medium adjusted to
pH 5.8 with HCl at 37°C and in the absence of CO2. Untreated cells
from an identical passage were used as controls. After all treatments,
cells were trypsinized for 1 minute, washed, and resuspended in ice-
cold FACS buffer (PBS with 10% FBS and 0.02% NaN3). To
detect externalized PE, cells were incubated with DLB (0.5 μg/ml)
for 1 hour. linDLB (0.5 μg/ml) was used as a negative control.
Bavituximab (20 μg/ml) was used to detect exposed PS, and rituxan
(20 μg/ml) was used as a nonbinding control for bavituximab. Cells
were washed, and bound peptides were detected with Alexa Fluor
488–conjugated streptavidin (1:3000 in FACS buffer), and bound
antibodies were detected with goat antihuman IgG-Cy2 (1:3000).
Apoptotic cells were identified with propidium iodide. The cells were
analyzed with a FACScan flow cytometer (BD Biosciences).
Localization of Duramycin Peptides in Tumor-Bearing Mice
In Vivo
To detect PE on the surface of EC, DLB (100 μg) was injected
intravenously into tumor-bearing mice. Bavituximab (150 μg) and
linDLB (100 μg) were used as positive and negative controls, respec-
tively. The mice were killed after 60 minutes and perfused with hep-
arinized saline as described previously [15,22]. The tumor and major
organs were removed and snap-frozen, and 10-μm cryosections were
cut. Sections were incubated overnight with rat antimouse CD31 anti-
body (1:200 in 1% BSA). Goat antirat IgG-Cy3 was used to detect the
CD31 antibody. DLB was detected with Alexa Fluor 488–conjugated
streptavidin. Bavituximab was detected with goat antihuman IgG-Cy2.
Cell nuclei were counterstained with DAPI. PE-positive vessels were
classified as DLB+, CD31+-costained structures having vascular endo-
thelial cell morphology.
Detection of Hypoxia in PE-Positive Tumors
One hundred micrograms of DLB was injected intravenously into
male C57BL/6 mice bearing RM-9 tumors. Immediately afterward,
2 mg of pimonidazole HCl (Hypoxyprobe-1 kit, Burlington, MA)
was injected intraperitoneally. After 1 hour, tumors were harvested
and sections were prepared as described previously [22]. Sections were
incubated overnight with rat antimouse CD31 IgG antibody (1:200)
and fluorescein isothiocyanate–labeled antibody against the pimonida-
zole adduct (Hypoxyprobe-1 kit) (1:50) in 1% BSA. The following
day, sections were stained with saturating amounts of Cy3-conjugated
streptavidin (1:500) to detect DLB. After washing, the sections were
incubated with biotinylated goat antirat IgG (1:500) followed with
Alexa Fluor 350–conjugated streptavidin (1:500) to detect the CD31
antibody. Immunohistochemical staining for pimonidazole adduct
formation was also used to compare levels of hypoxia in similar-sized
(1-cm-diameter) RM-9 tumors and 4T1 tumors. For each tumor type,
multiple fluorescent images were captured at low magnification (100×),
and hypoxia staining was quantified using ImageJ software.
Imaging of Tumors with 800CW-DUR
In vivo near-infrared fluorescence imaging was performed using a
Xenogen IVIS Lumina imaging system (Xenogen, Alameda, CA).
800CW-DUR (50 μg) was injected into a tail vein in male mice
bearing RM-9 tumors. 800CW-linDUR (50 μg) was used as a control.
Twenty-four hours after injection, mice were anesthetized with 2% iso-
flurane (Halocarbon, North Augusta, SC), and images were obtained.
Fluorescence (photons/sec per squared centimeter per steradian) was de-
tected using the NIR filter set (excitation between 605 and 780 nm
and emission between 810 and 885 nm).
Results
Modification of Duramycin to Create the PE-Binding Probes
DLB and 800CW-DUR
DLB was produced by reacting duramycin with the NHS ester of
L-biotin (Figure 1A). Lipid binding was assessed by ELISA. Figure 1A
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shows that DLB binding was specific for PE with maximum binding
occurring at ∼0.5 μg/ml (0.2 μM). Although some binding to PC
was observed at the higher concentrations, binding to PS, PI, PA,
and SM was undetectable. 800CW-DUR for noninvasive in vivo
imaging was produced by reacting duramycin with the NHS ester
of IRDye 800CW (Figure 1B). Similar to DLB, the IR probe
(800CW-DUR) demonstrated specificity for PE up to ∼5 μg/ml
(Figure 4B). Maximal binding occurred at ∼5 μg/ml (1.7 μM). Thus,
modification of duramycin by conjugation to L-biotin did not change
its affinity or specificity of binding to PE. DLB lysed 50% of murine
red cells at 80 μM compared with 20 μM for duramycin itself,
showing that biotinylation reduced the hemolytic activity of duramy-
cin by fourfold.
DLB Binds to PE on the Surface of Irradiated EC
We have previously shown that binding of fluorescent liposomes
coated with duramycin or bavituximab to ABAE cells is enhanced by
x-irradiation [2]. Here, we used biotinylated duramycin (DLB) with
FACS analysis and immunofluorescence staining to detect PE on the
surface of nonirradiated and irradiated ABAE cells. Figure 2A shows
that DLB bound to 37% of control ABAE cells. Irradiation increased
DLB binding to 93% of the cells and increased their median fluores-
cence intensity by fourfold to fivefold. Consistent with previous data
showing that irradiation induces PS externalization, immunofluores-
cence analysis of the cells 24 hours after 5-Gy irradiation showed that
both DLB (PE) and bavituximab (PS) bound to membrane blebs
(Figure 2B).
Figure 2. DLB binds PE exposed on cultured EC. DLB was used to detect PE on the surface of irradiated ABAE cells. (A) FACS analysis of
DLB-labeled ABAE cells that were untreated (upper panels) or had been irradiated with 5 Gy 24 hours earlier (lower panels). (B) Cells
were incubated with DLB or bavituximab, and binding was detected with streptavidin–Alexa Fluor 488 and Cy2–goat antihuman Ig,
respectively. LinDLB was used as a negative control for DLB. The cells were counterstained with Texas Red–labeled phalloidin.
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Induction of PE Exposure on Cultured EC by ROS, Hypoxia,
and Low pH
Flow cytometry was used to assess PE levels on EC after treatment
with different inducers of oxidative stress present in the tumor micro-
environment. About 30% of cultured EC had exposed PE before
treatment. Irradiation, H2O2, low pH, and hypoxia increased the
percentage of cells expressing PE from ∼35% to between 70% and
90% (Figure 3). Treatment with VEGF did not influence the exter-
nalization of PE. Similar trends were seen when bavituximab was
used to stain externalized PS. Bavituximab did not stain resting
EC, but stained 10% to 25% of the cells after they had been treated
with irradiation, H2O2, low pH, or hypoxia.
DLB Localizes to Tumor Blood Vessels
Intravenously injected DLB localized to tumor vessels in all tu-
mors examined (Table 1 and Figure 4). PE-positive vessels were iden-
tified from colocalization of DLB with CD31-stained structures
having a vascular morphology. Among the implanted solid tumor
models, the endothelium in syngeneic RM-1 and RM-9 prostate car-
cinomas displayed the highest levels of exposed PE with ∼50% of the
vessels staining positive. Orthotopically implanted human (MDA-
MB-231) and mouse (4T1) breast carcinomas displayed ∼29% and
∼13% PE-positive blood vessels, respectively. Spontaneously develop-
ing breast tumors in MMTV-PyMT transgenic mice contained 44%
PE-positive vessels (Figure W1).
The fraction of PE-positive blood vessels in each tumor model
correlated with the fraction of PS-positive blood vessels detected
with bavituximab (Table 1 and Figure 4). Coinjection of DLB and
bavituximab into mice bearing subcutaneous RM-9 tumors revealed
that the same tumor blood vessels were positive for both PE and PS
(Figure W2). The pattern of DLB staining generally resembled that
of bavituximab, with both demonstrating relatively homogeneous
costaining with CD31. However, some DLB-positive vessels also
exhibited punctate staining (as in Figure W2) that may indicate re-
gions of endothelium having membrane blebs similar to those seen
on cells in tissue culture. DLB bound specifically to PE exposed on
the tumor endothelium and did not seem to extravasate from the
blood vessels and bind tumor cells or become trapped within the in-
terstitium. Intravenously injected linDLB did not localize to tumor
blood vessels.
The binding of DLB to vasculature was largely restricted to tumor
blood vessels. DLB did not localize to the endothelium in the heart,
lung, liver, spleen, stomach, intestine, muscle, fat, brain, or testis
(Table 1 and Figure W3). In the kidney, DLB did not stain endothe-
lium in the glomeruli or larger vessels but did stain endothelium in
intertubular vessels between the distal tubules. DLB also showed dif-
fuse staining of the distal kidney tubules themselves and, to a lesser
extent, of proximal tubules. DLB uptake by the kidneys was not
unexpected because the urinary system is the main route by which
duramycin is eliminated from the body [23,24]. DLB also stained a
population of CD31-negative cells in the liver, which appeared from
their morphology to be Kupffer cells.
DLB Binding Is High in Hypoxic Areas of Tumors
Abnormal angiogenesis in tumors often results in malformed
blood vessels that fail to provide adequate blood flow throughout
the tumor. Therefore, specific areas within a tumor are subject to
acute ischemic hypoxia that is often transient [25,26]. Because hyp-
oxia induced PE exposure in in vitro–cultivated EC (Figure 3), we
determined whether tumors growing in mice also expressed PE in
hypoxic regions. Mice bearing similar-sized (1-cm-diameter) RM-9
or 4T1 tumors were injected with DLB to detect PE and pimonidazole
to assess hypoxia. The mice were killed 1 hour after injection and
perfused with saline, and frozen sections of tumors were examined
by immunohistochemistry. The results presented in Figure 5 show a
correlation between the distribution of PE-positive (red) EC and hyp-
oxic regions (green) of the tumor. RM-9 tumors, in which PE-positive
Figure 3. Multiple stresses associated with the tumor microenvi-
ronment induce increased PE exposure on cultured EC. Flow cy-
tometry was used to assay PE levels on ABAE cells after 1)
treatment with 10 μM H2O2 to simulate ROS, 2) incubation in me-
dium at pH 5.8 for 24 hours, 3) incubation under hypoxic con-
ditions (1% O2, 94% N2, 5% CO2) followed by reoxygenation for
4 hours (5% CO2 in air), and 4) treatment with 20 ng/ml VEGF. Ir-
radiation at 5 Gy was used as a positive control. Bavituximab was
used to detect PS externalization. Rituxan gave no staining (not
shown). LinDLB was used as a negative control for DLB.
Table 1. Percentage of PE-Positive Blood Vessels in Various Tissues.
Tissues DLB Bavituximab linDLB
Tumors
RM-1 47 ± 9 58 ± 12 0
RM-9 56 ± 3 60 ± 8 0
MDA-MB-231 29 ± 5 31 ± 8 0
4T1 13 ± 3 28 ± 5 0
B16 17 ± 5 18 ± 7 0
A549 21 ± 7 23 ± 6 0
MMTV-PyMT 41 ± 3 0
Normal
Heart 0 0 0
Lung 0 0 0
Liver 0 0 0
Kidney 45 ± 10 0 0
Spleen 0 0 0
Stomach 0
Intestine 0
Bladder 0
Muscle 0
Fat 0
Brain 0
Testes 0
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vessels were abundant, had large areas of hypoxia throughout the
tumor, whereas 4T1 tumors, in which PE-positive vessels were sparse,
had smaller, more localized areas of hypoxia and much less hypoxia
overall (Figure W4). Hypoxic regions were most pronounced around
necrotic regions and in central areas of the tumor. Consistent with
previous localization experiments, DLB stained greater than 50% of
the blood vessels in the RM-9 tumors. Most of the DLB-positive
vessels were located in and around the hypoxic regions (Figure 5,
top right panel ). The control peptide linDLB did not bind tumor
EC (not shown).
In Vivo Tumor Imaging with 800CW-DUR
To determine the ability of duramycin to target tumor vasculature
in vivo, mice bearing subcutaneously implanted RM-9 tumors were
injected with 800CW-DUR. The distribution of the probe was de-
tected with the Xenogen IVIS imaging system (Xenogen, Alameda,
CA) 24 hours later. Images are shown in Figure 6. Remarkable de-
lineation of the implanted tumors was achieved in three of three
mice. No other normal tissues showed detectable accumulation of
label, with the exception of the kidneys that were strongly labeled.
Discussion
The major finding of this study is that PE becomes exposed on the
luminal surface of the vascular endothelium of tumors. PE exposure
is the most prominent in and around regions of hypoxia and is prob-
ably induced by oxidative stresses in the tumor microenvironment.
The PE-binding peptide duramycin tagged with a single molecule
of L-biotin was used to assess the presence of PE on the cell surface.
Biotinylation seems to have reduced the ability of duramycin to dis-
rupt cell membranes because the hemolytic activity of DLB was four-
fold lower than that of duramycin itself. This is likely attributable
to the increased hydrophilic character imparted by the water-soluble
biotin moiety. This change may explain why DLB stained cell sur-
face structures but not intracellular membranes at the concentra-
tions tested.
DLB staining indicated a fourfold to fivefold increase in exposure
of PE on irradiated EC. DLB strongly stained membrane blebs that
formed on the surface after irradiation. The pattern of DLB staining
in irradiated ABAE closely resembled that of bavituximab, suggest-
ing that both PE and PS preferentially localize to membrane patches
and blebs [2]. Unlike PS, basal levels of PE are exposed on normal
Figure 4. Exposure of PE on vascular endothelial cells in tumors. One hundred micrograms of DLB was injected intravenously into mice
bearing subcutaneous RM-9 prostate tumors. After 1 hour, mice were perfused, and tumors and major organs were harvested. Immu-
nohistochemical staining of frozen sections revealed that DLB (green) colocalized with the pan-endothelial marker CD31 (red) in tumors.
PE exposure was observed in multiple tumor types (Table 1). Bavituximab produced a similar staining pattern to DLB.
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(untreated) ABAE cells, either naturally or because ABAE cells do
not readily enter a fully resting state in culture. These observations
are consistent with data indicating that essentially all the membrane
PS and ∼80% of the membrane PE are restricted to the cells plasma
membrane inner membrane leaflet [27]. Increased PE exposure has
also been shown at the cell surface along the cleavage furrow in Chinese
hamster ovary cells during cytokinesis and in a subset of EC in the
rat aorta [28,29]. Although PS and PE are both externalized during
apoptosis and in response to stress, PS is more highly restricted to
the inner membrane leaflet in healthy cells.
FACS analysis revealed that stress conditions associated with the
tumor microenvironment induced significant PE exposure when
applied to in vitro–cultivated EC. Tumors are known to contain
high levels of ROS owing to a number of dysregulated metabolic pro-
cesses. These include growth factor–mediated activation of mitochon-
dria, inflammatory responses from tumor-infiltrating leukocytes, and
activation/overexpression of enzymes such as NADPH-oxidase [30–
32]. Transient hypoxia in tumors can lead to ROS generation by this
last mechanism (i.e., activation of NADPH-oxidase) [13]. In addition
to high ROS levels, the tumor microenvironment is also often charac-
terized by low pH relative to normal tissues. Tumor cells can undergo
high rates of glycolysis irrespective of oxygen tension (the Warburg
effect) and generate lactic acid as a byproduct [33]. We found that
the fraction of ABAE that expressed PE at the cell surface after treat-
ment with ROS (H2O2), hypoxia, or acidic medium significantly in-
creased (Figure 3). These stresses also induced PS exposure. These
observations suggest that ROS, hypoxia, and acidic pH, possibly in
concert with other factors (e.g., inflammatory cytokines and throm-
bin), promote the exposure of PE and PS in tumors.
Without exception, increased PE exposure was found on the tu-
mor endothelium in all the tumors examined. These models included
syngeneic, human xenografts, subcutaneous, orthotopic, and trans-
genic tumors. This suggests that, much like PS, PE functions as a
broad tumor marker common to many malignancies. The percentage
of PE-positive vessels varied between models but corresponded to the
fraction of PS-positive vessels (determined by bavituximab binding)
Figure 5. PE exposure on tumor vessels is predominately in hypoxic areas. Mice bearing subcutaneous RM-9 prostate tumors were in-
jected with DLB to detect PE and pimonidazole HCl to detect hypoxia. Immunohistochemical staining of frozen sections demonstrated that
PE exposure on tumor vessels occurred predominantly in hypoxic areas of the tumor. Blue indicates CD31; green, hypoxia; red, DLB.
Figure 6. In vivo imaging of RM-9 tumors with 800CW-DUR. Male athymic nu/nu mice bearing subcutaneous RM-9 tumors in their right-
hind flank were injected with 50 μg of 800CW-DUR. 800CW conjugated to linear duramycin was used as a negative control (800CW-
linDUR). The mice were imaged after 24 hours with a Xenogen IVIS Lumina imaging system. Fluorescence intensity is displayed as
photons per second per squared centimeter per steradian.
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for each type of tumor. Moreover, the exposure of PE and PS occurred
on the same tumor vessels, suggesting that the same mechanism is re-
sponsible for the redistribution of both PE and PS. Tumor-bearing
mice were coinjected with DLB and pimonidazole HCl to assess hyp-
oxia in areas immediately surrounding PE-positive blood vessels. A
general correlation between DLB binding and pimonidazole staining
showed that PE-positive vessels were concentrated in hypoxic portions
of the tumor. RM-9 tumors, which have abundant PE-positive vessels,
were markedly hypoxic, whereas 4T1 tumors, which have relatively few
PE-positive vessels, were largely not hypoxic. These results further in-
dicate that hypoxia and other stresses in hypoxic tumor regions drive
PE exposure on tumor vasculature.
Despite evidence from in vitro experiments that normal EC con-
tain basal levels of PE on their surface, DLB did not localize to endo-
thelium in heart, lung, liver, spleen, stomach, intestine, muscle, fat,
brain, or testis. This difference might be because EC grown in vitro
are activated because of sustained low levels of chronic stress that pro-
mote higher levels of exposed PE, whereas EC in normal tissues in vivo
attain true quiescence. The transport enzymes that maintain mem-
brane lipid asymmetry have a higher affinity for PS, and its rate of
PS transport is approximately 10-fold higher than its rate of PE trans-
port [27,34]. This could explain why stress has a more profound ef-
fect on the redistribution of PE.
The selective exposure of PE on tumor vascular endothelium sug-
gested that it might serve as a marker for imaging tumor vasculature.
Being luminally exposed and in direct contact with the blood, we
reasoned that fluorescently labeled derivatives of duramycin would
localize rapidly and specifically to tumor endothelium. To test this hy-
pothesis, we labeled duramycin with a near-infrared dye, 800CW, and
injected it into mice bearing RM-9 prostate tumors. The biodistribu-
tion of injected 800CW-DUR confirmed that the levels of exposed PE
are indeed high in tumors. 800CW-DUR binding to RM-9 tumors
allowed them to be clearly distinguished above background fluores-
cence, suggesting that PE-specific probes may be a powerful tool
for tumor imaging. However, both 800CW-DUR and DLB showed
high uptake in the kidneys, as observed by Zhao and Bugenhagen [19]
with 99mTc-duramycin. Immunohistochemical analysis revealed that
DLB localized strongly to the distal kidney tubules and less strongly
to the proximal kidney tubules. DLB also stained intertubular blood
vessels between distal tubules, although it did not bind endothelium
in larger renal vessels or the glomeruli. Other studies have shown that
duramycin forms ion channels in artificial membranes and can dis-
rupt mitochondrial membranes at concentrations greater than 5 μM
[35,36]. Cinnamycin has also been shown to be toxic and promote its
own binding by inducing flipping of membrane lipids [37]. It is pos-
sible that, as the kidneys filter DLB or 800CW-DUR from the blood,
local concentrations of the drug in the collecting ducts and the asso-
ciated vasculature increase to the extent that it disrupts membranes
and exposes PE.
In conclusion, the data presented in this report demonstrate that
PE becomes exposed on the luminal surface of tumor vascular endo-
thelium. PE seems to be a broad marker found in a number of mouse
models of solid malignancies including spontaneously developing
tumors. We demonstrate that PE on tumor vasculature can be im-
aged with PE-targeting probes. These probes are small compared
with PS-targeting antibodies and annexins, and clear rapidly from
the bloodstream making them particularly suitable for imaging pur-
poses. In addition, PE is more abundant than PS, giving the potential
for stronger signals. Indeed, duramycin labeled with 99mTc is being
developed for imaging exposed PE in cardiac ischemia [19]. The re-
sults reported herein suggest that PE also has potential as a marker
for imaging human malignancies.
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Figure W1. DLB localizes to vasculature in spontaneously developing PyMT breast tumors. One hundred micrograms of DLB was in-
jected intravenously into female PyMT mice bearing palpable breast tumors (∼0.3 cm in diameter). After 1 hour, mice were perfused,
and tumors and major organs were harvested. Immunohistochemical staining of frozen sections revealed that DLB (green) colocalized
with the pan-endothelial marker CD31 (red) in tumors.
Figure W2. DLB and bavituximab colocalize to the same tumor vessels after intravenous injection. Then, 150 μg of bavituximab and
100 μg of DLB were injected intravenously into mice bearing subcutaneous RM-9 prostate tumors. After 1 hour, mice were perfused,
and tumors and major organs were harvested. Immunohistochemical staining of frozen sections revealed colocalization of DLB (red) and
bavituximab (green) on tumor blood vessels identified by CD31 staining (blue). Blebs that appear yellow or white are costained. Most of
the blebs that appear red in this merged image were also bavituximab positive, but the red color dominated the green color.
Figure W3. DLB localizes to tubules and intertubular vessels in the
kidney but does not localize to endothelium in other normal tis-
sues. One hundred micrograms of DLB was injected intravenously
into mice bearing subcutaneous RM-9 prostate tumors. After
1 hour, mice were perfused, and tumors and major organs were
harvested. Frozen sections were analyzed by immunohistochem-
istry. DLB was detected by Alexa Fluor 488–streptavidin (green),
CD31 was detected by rat antimouse CD31/goat antirat IgG-Cy3
(red), and cell nuclei were detected by DAPI (blue). DLB bound
to the proximal (p) and distal (d) collecting tubules of the kidney.
DLB also bound to the intertubular blood vessels (arrow) between
distal tubules. It did not stain endothelium in larger blood vessels
(v) or in the glomeruli (g). DLB did not bind to endothelium in the
heart, lung, liver, or spleen. DLB stained CD31-negative cells in the
liver that appear to be Kupffer cells (arrows).
Figure W4. RM-9 prostate tumors are more hypoxic than 4T1
breast tumors. Pimonidazole HCl was injected into mice bearing
either subcutaneous RM-9 tumors or orthotopic 4T1 tumors to de-
tect hypoxia. Immunohistochemical staining of frozen sections re-
vealed that RM-9 tumors were markedly hypoxic throughout,
whereas 4T1 tumors had smaller, more discrete, areas of hypoxia.
Green indicates hypoxia; red, CD31. The greater hypoxic fraction
in RM-9 tumors may explain the greater percentage of PE-positive
vessels in these tumors compared with 4T1 tumors.
